Alamar Biosciences, Inc. (ALMR)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Alamar Biosciences: Promising But Expensive Proteomics Growth
Alamar Biosciences' ARGO instruments automate NULISA assays. This creates a platform that can convert placements into recurring consumables' demand. I concede that ALMR's broader disease panels and sampling could also deepen the utilization of its platform and expand its long-term TAM even into diagnostics. The good news is that consumables are growing faster than instruments. But we need to see if this will be long-term profitable growth as the installed base expands.
Alamar Biosciences Q2 Earnings Call Highlights
Alamar Biosciences NASDAQ: ALMR reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company's first earnings call since completing its April initial public offering.
Alamar Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Farallon Capital Farallon Capital Management LLC | 462,900 | $12.54M | $13M | $460,909.53 | 3.68% |
 George Soros Soros Fund Management LLC | 60,000 | $1.63M | $1.41M | -$214,200 | -13.18% |
| CD Charlie Durham Sterling Capital Management LLC | 115 | $3,115 | $3,194.42 | $79.42 | 2.55% |
 Point72 Asset Management LP Point72 Asset Management LP | 51,800 | $1.4M | $1.42M | $17,094 | 1.22% |
 Joseph Castro Nuveen LLC | 24,528 | $664,464 | $680,899.73 | $16,435.73 | 2.47% |
Alamar Biosciences, Inc. (ALMR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alamar Biosciences, Inc. ever had a stock split?
Alamar Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Yuling Luo CEO | NASDAQ (NGS) Exchange | 010911105 CUSIP |
| US Country | 222 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Alamar Biosciences is a pioneering company in the field of proteomics, designed to cater to both research and clinical applications. The organization specializes in ultra-sensitive and multiplexed protein detection, offering capabilities that enable scientists and healthcare professionals to measure multiple low-abundance proteins with remarkable accuracy. Alamar's integrated platform includes proprietary instruments, consumables, and advanced software, all tailored to deliver a seamless end-to-end system for protein analysis, positioning the company on the forefront of biotechnological advancements.
Products and Services
- Proprietary Instruments
Alamar Biosciences has developed specialized instruments designed to detect low-abundance proteins with outstanding sensitivity. These cutting-edge devices are essential for researchers looking to explore protein interactions and functions at unprecedented levels. The technology behind these instruments enables reliable and reproducible measurements, which are critical for advancing scientific understanding.
- Consumables
The consumables offered by Alamar are integral components of the protein detection process. These high-quality reagents and materials are specifically formulated to work seamlessly with Alamar's instruments, ensuring optimal performance and accuracy in protein assays. Researchers can depend on these consumables to provide consistent results across various experimental conditions.
- Advanced Software
Alamar's robust software solutions are designed to facilitate the analysis and interpretation of complex proteomics data. The software integrates with the proprietary instruments to process and visualize data effectively, allowing researchers to derive meaningful insights with ease. Its user-friendly interface simplifies the workflow, making it accessible for both experienced scientists and newcomers to the field.
- Research and Development Support
Alamar Biosciences offers extensive support for research and development projects. This includes consultation services, guidance in experimental design, and collaboration opportunities for researchers aiming to leverage proteomics for innovative scientific discoveries. The company aims to foster partnerships that drive advancements in biomedicine and related fields.
- Clinical Application Development
In addition to its focus on research, Alamar is committed to exploring future clinical applications of its technology. The company actively collaborates with medical institutions to develop assays and diagnostic tools that utilize ultra-sensitive protein detection for improved patient outcomes. This initiative is indicative of Alamar’s dedication to translating research advancements into real-world healthcare solutions.
Contact Information
